Loading...
Phase I Trial of Fenretinide Delivered Orally in a Novel Organized Lipid Complex in Patients with Relapsed/Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium
BACKGROUND: A phase I study was conducted to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4-HPR) delivered in an oral powderized lipid complex (LXS) in patients with relapsed/refractory neuroblastoma. PROCEDURE: 4-HPR/LXS powder (352 - 2...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4066886/ https://ncbi.nlm.nih.gov/pubmed/23813912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24643 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|